CN101039677A - 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法 - Google Patents

利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法 Download PDF

Info

Publication number
CN101039677A
CN101039677A CNA200580034824XA CN200580034824A CN101039677A CN 101039677 A CN101039677 A CN 101039677A CN A200580034824X A CNA200580034824X A CN A200580034824XA CN 200580034824 A CN200580034824 A CN 200580034824A CN 101039677 A CN101039677 A CN 101039677A
Authority
CN
China
Prior art keywords
optionally substituted
propyl
methyl
dione
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580034824XA
Other languages
English (en)
Chinese (zh)
Inventor
曾德婉
迈克尔·R·布莱克本
路易斯·贝拉尔迪内利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN101039677A publication Critical patent/CN101039677A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA200580034824XA 2004-10-15 2005-10-14 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法 Pending CN101039677A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61943904P 2004-10-15 2004-10-15
US60/619,439 2004-10-15

Publications (1)

Publication Number Publication Date
CN101039677A true CN101039677A (zh) 2007-09-19

Family

ID=35677798

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580034824XA Pending CN101039677A (zh) 2004-10-15 2005-10-14 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法

Country Status (13)

Country Link
US (2) US20060159627A1 (enExample)
EP (2) EP2311462A1 (enExample)
JP (2) JP2008516969A (enExample)
KR (1) KR20070063548A (enExample)
CN (1) CN101039677A (enExample)
AU (1) AU2005295654B2 (enExample)
CA (1) CA2583986A1 (enExample)
IL (1) IL182493A0 (enExample)
MX (1) MX2007004373A (enExample)
NO (1) NO20072466L (enExample)
NZ (2) NZ589657A (enExample)
RU (1) RU2391103C2 (enExample)
WO (1) WO2006044610A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103237548A (zh) * 2010-06-30 2013-08-07 吉利德科学股份有限公司 A2b腺苷受体拮抗剂用于治疗肺高血压的应用
CN116322698A (zh) * 2020-09-04 2023-06-23 泰昂治疗公司 腺苷a2b受体拮抗剂的共晶

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
AU2003259264A1 (en) * 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
RU2357969C2 (ru) * 2003-08-25 2009-06-10 АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
WO2008051260A1 (en) * 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CN101511366B (zh) * 2006-09-01 2011-12-28 吉利德帕洛阿尔托股份有限公司 在心肌显像方法期间用于增加患者耐受性的方法和组合物
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
WO2010037122A1 (en) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
CA2755117C (en) 2009-03-13 2018-09-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
AR085942A1 (es) * 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
CN107249630A (zh) * 2014-11-24 2017-10-13 国家健康与医学研究院 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
CA3093234A1 (en) 2018-03-05 2019-09-12 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
MXPA02002262A (es) * 1999-08-31 2002-09-30 Univ Vanderbilt Antagonistas selectivos de los receptores adenosina a2b.
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2400206A1 (en) 2000-02-17 2001-08-23 Cv Therapeutics, Inc. Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
RU2318824C2 (ru) 2001-11-09 2008-03-10 Си Ви Терапьютикс, Инк. Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6933298B2 (en) * 2001-12-08 2005-08-23 Aventis Pharma Deutschland Gmbh Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases
BR0215202A (pt) * 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
ES2229928B1 (es) 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
US7449473B2 (en) 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
CA2578702A1 (en) 2004-09-01 2006-03-16 Cv Therapeutics, Inc. Method of wound healing using a2b adenosine receptor antagonists
NZ564326A (en) 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
US7795268B2 (en) 2006-03-17 2010-09-14 Gilead Palo Alto, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103237548A (zh) * 2010-06-30 2013-08-07 吉利德科学股份有限公司 A2b腺苷受体拮抗剂用于治疗肺高血压的应用
CN116322698A (zh) * 2020-09-04 2023-06-23 泰昂治疗公司 腺苷a2b受体拮抗剂的共晶

Also Published As

Publication number Publication date
JP2008516969A (ja) 2008-05-22
AU2005295654B2 (en) 2011-04-14
US20060159627A1 (en) 2006-07-20
IL182493A0 (en) 2007-09-20
NZ589657A (en) 2012-06-29
MX2007004373A (es) 2007-08-08
RU2391103C2 (ru) 2010-06-10
EP2311462A1 (en) 2011-04-20
JP2012056965A (ja) 2012-03-22
US8466129B2 (en) 2013-06-18
WO2006044610A1 (en) 2006-04-27
RU2007117907A (ru) 2008-11-20
AU2005295654A1 (en) 2006-04-27
CA2583986A1 (en) 2006-04-27
NO20072466L (no) 2007-05-14
EP1799221A1 (en) 2007-06-27
US20100105706A1 (en) 2010-04-29
NZ554485A (en) 2010-12-24
KR20070063548A (ko) 2007-06-19

Similar Documents

Publication Publication Date Title
CN101039677A (zh) 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
CN1585769A (zh) A2b腺苷受体拮抗剂
CN1882588A (zh) A2b腺苷受体拮抗剂
CN1244589C (zh) 腺苷a3受体激动剂
CN1154494C (zh) 腺苷a3受体调节剂
CN1890241A (zh) A2b腺苷受体拮抗剂
CN1146566C (zh) 2-芳基-8-氧代二氢嘌呤衍生物及其制备方法、含该衍生物的药物组合物、及其中间体
CN1197621C (zh) 促进排便的药物组合物
CN1149215C (zh) 苯基黄嘌呤衍生物
CN1894250A (zh) 取代的8－杂芳基黄嘌呤
CN1882591A (zh) 具有PDE－5抑制活性的5,7－二氨基吡唑并[4,3－d]嘧啶
CN1056879A (zh) 吡咯衍生物及其制备方法
CN1946405A (zh) 9h－嘌呤－2,6－二胺衍生物在治疗增殖性疾病中的应用以及新的9h－嘌呤－2,6－二胺衍生物
CN1331591A (zh) 用作趋化因子受体5调节剂的氮杂二环烷烃
CN101031569A (zh) 作为人磷脂酰肌醇3－激酶δ抑制剂的喹唑啉酮
CN1503793A (zh) N-取代的非芳基-杂环nmda/nr2b拮抗剂
KR20080107416A (ko) Ａ2ｂ 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법
CN1745080A (zh) 1,3－二氢－咪唑稠环化合物
CN1771250A (zh) 作为a2b腺苷受体拮抗剂的黄嘌呤衍生物
CN1882586A (zh) 用于治疗蛋白激酶依赖性疾病的1h－咪唑并[4,5－c]喹啉衍生物
CN1251589A (zh) 为gaba受体配位体的取代的三唑并哒嗪衍生物
CN1422273A (zh) 1,5－二取代－3,4－二氢－1H－嘧啶并[4,5－d]嘧啶二酮化合物和其在治疗CSBP/p38激酶介导的疾病中的用途
CN1993363A (zh) 1,3－二取代的杂芳基nmda/nr2b拮抗剂
CN101043889A (zh) 使用a2b腺苷受体拮抗剂促使伤口愈合的方法
CN1104432C (zh) 吡咯并三嗪和嘧啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070919